Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. - Wikidata - wikimedia - TriplyDB

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

http://www.wikidata.org/entity/Q36854122

about

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Signal transduction in the chronic leukemias: implications for targeted therapies Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases The PIM kinases in hematological cancers mTOR and cancer therapy Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.The evolution of the TOR pathway and its role in cancer.mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells.Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.A common phosphotyrosine signature for the Bcr-Abl kinase.GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.mTOR signaling: implications for cancer and anticancer therapy.Emerging Flt3 kinase inhibitors in the treatment of leukaemia.Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Current therapeutic strategies for acute myeloid leukaemia.The exploration of network motifs as potential drug targets from post-translational regulatory networks Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Mechanisms of resistance to FLT3 inhibitors.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

P2860

Q24299821-62D0016D-25FE-48A5-B9B1-1599E08A5642 Q26829652-A9A7D0A0-30CF-49D6-AD8F-5EFE49A40E60 Q27026031-2D5D7782-D79A-4292-A874-3F6CF151AD61 Q27652488-6BBA56A5-0756-400E-9C45-B8D26960A19D Q28258028-5D4027B0-47BB-4EB6-94FC-C754452F4353 Q28268516-00E9B67F-B89F-4DFE-9916-6AAADFFA14EC Q29617473-8222B28C-7A46-4507-9832-79DCBD3472DA Q33597663-7560E110-AC9E-4A4B-9CBE-3DCA0461A248 Q34004131-1F482D96-5B8B-4D16-850B-ABF0097E8F87 Q34004994-26C2437C-5C38-4E9C-9AD6-167C7695497D Q34030154-D870AD14-4F0F-49FB-9B8E-A6284F2ECE5A Q34097586-22F419C5-88B7-429E-8A73-5AFC474B05FB Q34318188-08E29137-0D45-49B7-A2A1-4881299BF267 Q34360637-ED3B8A3F-0887-415F-82CB-1AFEDDE8215F Q35036482-E1FFD1F7-C8D5-4A0C-8135-39461E694DD5 Q35048118-ACDC1D65-C4A4-4501-B66B-FD6E0A2848CD Q35212394-5243C864-35E4-4A8C-8CA9-07E9D5DE03F9 Q35608171-D5BB5D2A-6C4C-4BD6-A44E-07E03C7E7A0B Q35664319-6550F4C8-EB28-4CA0-861B-2F0146A99EF0 Q35782919-71DB050E-27BA-4592-9CCA-11189576D2C3 Q35832116-DA79C773-A14C-4D06-801E-147CB51ECB35 Q35849758-3FA565EB-4A0C-4F01-8FA5-6C9220C074ED Q35853026-992AAED4-D15D-43B8-A060-B061C9502C20 Q35875753-62749235-7347-46FC-B5E2-4A769BA83E49 Q35931271-304180E9-5F96-4BC2-8284-189EC8266732 Q36334327-468F85A4-545D-43D6-A329-31A1412EE9B2 Q36365093-E96E1202-F16C-4C1F-A4F7-A177F8FEBA89 Q36407425-98E7DABC-C43E-40F8-BC12-5DDDD0BD47DB Q36508937-8BA264D7-2A35-4690-9A2C-AD5A0A2A393C Q36539598-7B14CFFB-2E14-49CB-8086-470C243DE751 Q36555138-6EA29A92-F33C-4C86-B2C1-1A07D016C283 Q36600294-6B07E061-5745-4F45-BA83-BA341022C5D8 Q36604270-508A86CE-6291-49FA-B7A6-E4B2BDFE6C3A Q36742629-EC8FC7E5-DD35-42CD-9D71-34FC10024DD3 Q36749168-6ACE2F19-F1D8-4B21-B9AF-D8E5A07C6EA4 Q36822880-45FCDE08-AAC2-4CAF-8F89-B2F17B93A400 Q36835733-FA09EF1C-4C3E-418F-8F5C-67B126D959B8 Q36844334-65D44A95-8E8E-4361-A5E9-52A29C44F63F Q37375423-296D2024-18F1-4DD0-842F-CB6458F83BF7 Q37432231-133A991E-D52C-4266-A34A-B19D6C6C0DA7

P2860

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

http://www.wikidata.org/entity/Q36854122

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Combination of rapamycin and p ...... mias caused by oncogenic PTKs.

@en

type

label

Combination of rapamycin and p ...... mias caused by oncogenic PTKs.

@en

prefLabel

Combination of rapamycin and p ...... mias caused by oncogenic PTKs.

@en

P1433

Q36854122-FC0D4F54-6C76-40DD-80EA-C3DD4E7E4F64

P1476

Q36854122-376BDFA3-E211-4C40-A959-F2D5BE672DD3

P2093

Q36854122-04997278-3B0B-4667-946E-7AC13A4CA9DB

Q36854122-2E73A1F1-34C0-4A5B-B5A7-C213C5823A97

Q36854122-3503FEC1-F76C-4084-A526-2BD46CCA3903

Q36854122-3ADF4892-6452-45A1-BE16-87D28541A2C2

Q36854122-53B64709-429A-495A-8AD1-A976F10BC745

Q36854122-9C35A2B1-0234-423F-8E61-81112A388DC0

Q36854122-CEF7B504-E955-4D8D-94D1-23BC9DCF3056

Q36854122-ED2B5BDB-7ADA-44D0-AC35-B4115FF2E79B

P2860

Q36854122-1A3C7EEE-9115-47F9-A4EC-31256322568B

Q36854122-1B976E68-EDEF-48E4-A47F-BB6443EF13DE

Q36854122-1C817C56-9518-493F-8D96-5DE003981D43

Q36854122-22F7A1DE-EC09-40F5-8358-80B5C9FCF0A3

Q36854122-34946CD5-6293-4892-A5CB-3F1D7662C62A

Q36854122-38CB2781-A645-4F88-8951-4E8CEADDB6B0

Q36854122-3B1FFB12-F11D-4338-8214-66A0FC3F084E

Q36854122-3F80D2B4-5BF2-49EA-8485-78C7A8DD837F

Q36854122-437947E7-1BBB-43EB-9456-CF72EBE00207

Q36854122-448EBBFB-D7A1-4E0A-8B93-505DBD2EF6B5

P304

Q36854122-20AF5CAA-2AF2-4B2F-8343-3085C85F9013

P31

Q36854122-7F29B9F8-A437-45D0-8D4D-7CD74A606372

P356

Q36854122-FC7C89EF-60E1-41FE-B654-02F9C9D0D772

P407

Q36854122-12FC3598-868C-4C13-BFB0-A1060C5C6FAF

P433

Q36854122-26855AE6-BC50-40E0-A654-FF40514B634C

P478

Q36854122-9A3EBAA6-95B8-4B19-9996-FAD5F4AFF6B4

P577

Q36854122-E7B85200-4A83-4C1C-91E0-6961CC95B61C

P5875

Q36854122-05C187F2-598D-4BA2-97BC-B8ED6A2980FE

P698

Q36854122-6AA30AD6-14DC-47E2-B7CC-D9E29D7238B9

P932

Q36854122-40E1453C-BA27-44EC-B7F7-5DB2FCBDAECD

P356

PNAS.0400063101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Combination of rapamycin and p ...... mias caused by oncogenic PTKs.

@en

P2093

Benjamin G Neel

http://www.w3.org/2001/XMLSchema#string

Christina Boulton

http://www.w3.org/2001/XMLSchema#string

D Gary Gilliland

http://www.w3.org/2001/XMLSchema#string

David W Sternberg

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

M Golam Mohi

http://www.w3.org/2001/XMLSchema#string

Ting-Lei Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome

P304

3130-3135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0400063101

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8687624

http://www.w3.org/2001/XMLSchema#string

P698

14976243

http://www.w3.org/2001/XMLSchema#string

P932

365755

http://www.w3.org/2001/XMLSchema#string